A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)
A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)
The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.
Inclusion criteria:
Diet and exercise only (drug naïve), with HbA1c >7.0 and £ 10.0%. HbA1c > 6.5 and <= 8.5%.
Exclusion Criteria:
Capital Federal, Buenos Aires 1181, Argentina
Capital Federal, Buenos Aires C1155ADP, Argentina
Capital Federal, Buenos Aires C1437JCP, Argentina
Ciudad Autonoma de Buenos Aires, Buenos Aires B1704ETD, Argentina
Moron-Provincia de Buenos Aires, 1709, Argentina
Sr. Ingbert, Saarland 66386, Germany
Pokfulam, Hong Kong
Marid, 28040, Spain
San Juan/Alicante, 03550, Spain